Hyperphosphatemia is a lot to manage.

Learn more about the need to substantially reduce pill burden in hyperphosphatemia for better patient outcomes

Arrow pointing down

The unmet need in hyperphosphatemia

Despite the availability of 6 FDA-approved phosphate binders, hyperphosphatemia remains uncontrolled in an estimated 75% of US dialysis patients1

Serum Phosphorus (3-month average)1
< 4.5 mg/dl
> 4.5 mg/dl
Serum Phospherous Chart of the 3 Month Average
60%

In a survey of 100 US-based nephrologists, 60% named high pill burden leading to patient non-adherence as the greatest unmet need in hyperphosphatemia.2

The daily burden for dialysis patients

19

Pills per day (median)
is the highest
across various chronic disease states3
49%
Of daily pill burden is due to
phosphate binders3

9

Phosphate binders
per day
(average) with current standard of care4

3 phosphate binders.

3x per day.

Every day.
Forever.
Forever.
Forever.
Forever.
Forever.
Forever.
Forever.
Forever.
Forever.
Forever.
Forever.
Forever.
Forever.
Forever.
Forever.
Forever.
Forever.
Forever.
Forever.
Forever.
Forever.
Forever.
Forever.
Forever.
Forever.
Forever.
Forever.
Forever.

62%

of patients are
non-adherent
(self reported)
Three White Pills

It's time to do more with less.

By enhancing potency through its patented nanoparticle technology, Unicycive aspires to dramatically reduce the pill burden in hyperphosphatemia. 



Ready for less pill burden?

Sign up to stay up to date with the latest news and information.

By clicking "Sign Up", you agree to receive emails at the email address listed above. You also agree to Unicycive’s Privacy Policy and Terms of Use.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

References: 1. US-DOPPS Practice Monitor, May 2021; http://www.dopps.org/DPM 2. Data on file. Unicycive Therapeutics, Inc; 2022. 3. Chiu YW, Teitelbaum I, Misra M, et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009 Jun;4(6):1089-96. 4. Sanofi-Genzyme Corporation. Renvela (sevelamer carbonate) tablet, film coated. 2000 [rev. 2023 Sep; cited 2023 Sep]. In: DailyMed [Internet]. [2005] - , [about 27 p.]. Bethesda (MD): National Library of Medicine (US). Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6328460-a57b-450b-a48c-6dcd4b476360

About UnicycivePrivacy PolicyTerms of UseContact Us
Unicycive Therapeutics Logo
©️ 2023 Unicycive Theraputics, Inc. All rights reserved.